Adverum Biotechnologies(ADVM) - 2020 Q1 - Earnings Call Presentation

Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) Market Overview - Over 30 million people in the U S are living with diabetes, all at risk of DR[6] - DR affects approximately one in three (33%) adults with diabetes[6] - DME affects approximately 5% of people with diabetes[7] - The global sales for approved anti-VEGF therapies is $11 billion[6] - Standard-of-care therapy for DME is anti-VEGF intravitreal injections, which require frequent and long-term administration[6] ADVM-022 Gene Therapy - ADVM-022 is a one-time intravitreal injection for durable expression of therapeutic protein[7] - It produces codon-optimized aflibercept for efficient VEGF and PlGF inhibition[7,8] INFINITY Phase 2 Trial - The INFINITY trial is a Phase 2 clinical trial of ADVM-022 in Diabetic Macular Edema (DME)[2,9,10] - The trial will enroll approximately 33 patients and is designed to demonstrate superior disease control compared to a single aflibercept injection[10] - The primary objective is to assess the time to worsening of DME disease activity[9]